UCB Pharmaceuticals SWOT Analysis, USP & Competitors

UCB Pharmaceuticals

Parent Company

UCB Pharmaceuticals

Category

Pharmaceutical

Sector

Pharma and Healthcare

Tagline/ Slogan

Aspiring to be patient centric biopharma leader

USP

It is global biopharma focused on severe diseases with operations in over 40 countries

UCB Pharmaceuticals STP

Segment

Central nervous system diseases & immunology

Target Group

Healthcare professionals offering solutions to patients suffering from severe diseases

Positioning

A global biopharma focused in severe diseases focused in two areas namely CNS & immunology

UCB Pharmaceuticals SWOT Analysis

Strengths

1. UCB has nearly 9000 well trained employees

2. Strong global presence in over 40 countries

3. It has strong product pipeline with many molecules in last stages of development especially in case of CNS

4. They have four major blockbuster products such as Cimzia, Vimpat, Neutro, Keppra.

Weaknesses

1. Company operates in limited segments of medication for severe diseases only

2. It has limited presence in developing world as majority of revenue comes from America & Europe operations

Opportunities

1. There is good scope for development of new treatment options in epilepsy

2.  they can further utilize full potential of their blockbuster drugs

3. Increasing awareness about severe diseases

Threats

1. Economic instability of euro zone can hurt revenue of company

2. Strong FDA drug development guidelines

3. Increasing competition of other pharma majors in their business segments

UCB Pharmaceuticals Competition

Competitors

1. Abbott laboratories
2. Amgen

3. AstraZeneca

4. Forest laboratories